Treatments For Mild Cognitive Impairment Unlikely To Reduce Payer Costs – OptumInsight Exec
Mild cognitive impairment has become an important focus in research on treating Alzheimer’s disease, based on the drive toward early intervention. But a lack of data on the condition complicates the development of economic models that could persuade payers about the cost effectiveness of treatments.
You may also be interested in...
MedCAC panel has limited confidence that there is enough evidence to show beta amyloid positron emission tomography imaging of the brain changes health outcomes. The vote does not bode well for the technology’s coverage proposal due in July.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.